NASDAQ:AGEN - Agenus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.45 +0.10 (+2.99 %)
(As of 05/20/2018 03:41 PM ET)
Previous Close$3.45
Today's Range$3.32 - $3.49
52-Week Range$3.06 - $6.19
Volume900,732 shs
Average Volume1.47 million shs
Market Capitalization$358.80 million
P/E Ratio-2.80
Dividend YieldN/A
Beta1.66

About Agenus (NASDAQ:AGEN)

Agenus logoAgenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400

Debt

Debt-to-Equity Ratio-0.11
Current Ratio2.16
Quick Ratio2.16

Price-To-Earnings

Trailing P/E Ratio-2.80
Forward P/E Ratio-2.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$42.88 million
Price / Sales8.37
Cash FlowN/A
Price / CashN/A
Book Value($1.09) per share
Price / Book-3.17

Profitability

EPS (Most Recent Fiscal Year)($1.23)
Net Income$-120,690,000.00
Net Margins-281.49%
Return on EquityN/A
Return on Assets-98.89%

Miscellaneous

Employees255
Outstanding Shares104,000,000

Agenus (NASDAQ:AGEN) Frequently Asked Questions

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.14. View Agenus' Earnings History.

When is Agenus' next earnings date?

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Agenus.

What price target have analysts set for AGEN?

1 brokerages have issued 12 month price objectives for Agenus' stock. Their predictions range from $7.00 to $7.00. On average, they expect Agenus' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Agenus.

Who are some of Agenus' key competitors?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:
  • Dr. Garo H. Armen Ph.D., Founder, Exec. Chairman & CEO (Age 65)
  • Ms. Christine M. Klaskin, VP of Fin. (Age 52)
  • Ms. Karen Higgins Valentine, Chief Legal Officer & Gen. Counsel (Age 46)
  • Mr. Ozer Baysal, Chief Commercial Officer & Head of HR (Age 62)
  • Dr. Robert B. Stein Ph.D., M.D., Sr. R&D Advisor (Age 67)

Has Agenus been receiving favorable news coverage?

Media stories about AGEN stock have been trending somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agenus earned a daily sentiment score of 0.23 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.64 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Agenus' major shareholders?

Agenus' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.75%), Point72 Asset Management L.P. (3.34%), Artal Group S.A. (2.64%), Northern Trust Corp (0.93%), Millennium Management LLC (0.91%) and venBio Select Advisor LLC (0.68%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Corp Incyte, Garo H Armen, Karen Valentine and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.

Which major investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Millennium Management LLC, Candriam Luxembourg S.C.A. and Chicago Equity Partners LLC. Company insiders that have sold Agenus company stock in the last year include Alex Duncan, Christine M Klaskin and Karen Valentine. View Insider Buying and Selling for Agenus.

Which major investors are buying Agenus stock?

AGEN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Artal Group S.A., UBS Group AG, BlackRock Inc., Russell Investments Group Ltd., Northern Trust Corp, Barclays PLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Agenus stock in the last two years include Corp Incyte, Garo H Armen and Ulf Wiinberg. View Insider Buying and Selling for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $3.45.

How big of a company is Agenus?

Agenus has a market capitalization of $358.80 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]


MarketBeat Community Rating for Agenus (AGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  480
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agenus (NASDAQ:AGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Agenus in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 102.90%. The high price target for AGEN is $7.00 and the low price target for AGEN is $7.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.672.672.75
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$6.3333$6.3333$6.3333
Price Target Upside: 102.90% upside57.55% upside57.55% upside57.55% upside

Agenus (NASDAQ:AGEN) Consensus Price Target History

Price Target History for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Jefferies GroupReiterated RatingBuy$7.00HighView Rating Details
5/6/2017HC WainwrightSet Price TargetHold$5.00LowView Rating Details
4/23/2017Maxim GroupReiterated RatingBuy$7.00MediumView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Agenus (NASDAQ:AGEN) Earnings History and Estimates Chart

Earnings by Quarter for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.36)
2019 EPS Consensus Estimate: ($1.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.35)($0.35)($0.35)
Q2 20181($0.34)($0.34)($0.34)
Q3 20181($0.33)($0.33)($0.33)
Q4 20181($0.34)($0.34)($0.34)
Q1 20191($0.35)($0.35)($0.35)
Q2 20191($0.35)($0.35)($0.35)
Q3 20191($0.35)($0.35)($0.35)
Q4 20191($0.34)($0.34)($0.34)

Agenus (NASDAQ AGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/7/2018Q1 2018($0.28)($0.42)$16.39 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.28)($0.35)$5.30 million$8.30 millionViewListenView Earnings Details
11/7/2017Q3($0.37)($0.37)$5.91 million$3.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.36)($0.32)$6.66 million$4.21 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.32)($0.18)$5.22 million$26.96 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.30)($0.30)$6.01 million$5.58 millionViewListenView Earnings Details
10/27/2016Q316($0.32)($0.47)$6.15 million$4.45 millionViewListenView Earnings Details
7/28/2016Q216($0.34)($0.33)$5.12 million$6.59 millionViewListenView Earnings Details
4/28/2016Q116($0.23)($0.37)$6.74 million$5.96 millionViewListenView Earnings Details
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details
10/27/2015Q315($0.15)($0.16)$5.71 million$6.85 millionViewListenView Earnings Details
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details
4/23/2015Q115($0.15)($0.21)$11.66 million$3.95 millionViewN/AView Earnings Details
2/26/2015Q414($0.15)($0.18)$0.66 million$1.62 millionViewN/AView Earnings Details
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details
7/24/2014Q214($0.11)($0.12)$0.71 million$3.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)$0.01$0.55 million$0.7210 millionViewN/AView Earnings Details
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.21)($0.40)$1.18 million$0.81 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.19)($0.35)$1.13 million$1.11 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details
10/25/2012Q3 2012($0.28)($0.24)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.26)($0.31)ViewN/AView Earnings Details
4/25/2012Q1 2012($0.29)$0.29ViewN/AView Earnings Details
3/5/2012Q4 2011($0.28)($0.29)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.27)($0.28)ViewN/AView Earnings Details
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.24)($0.30)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.30)($0.18)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.36)($0.36)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.30)($0.32)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.36)($0.59)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.54)$0.11ViewN/AView Earnings Details
10/29/2009Q3 2009($0.66)($0.76)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.78)($1.02)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.72)($0.87)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.96)($0.65)ViewN/AView Earnings Details
11/5/2008Q3 2008($1.08)($1.01)ViewN/AView Earnings Details
7/31/2008Q2 2008($1.08)($1.13)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.84)($1.21)ViewN/AView Earnings Details
2/21/2008Q4 2007($1.38)($0.97)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Agenus (NASDAQ:AGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Agenus (NASDAQ AGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 35.94%
Insider Trading History for Agenus (NASDAQ:AGEN)
Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ AGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Alex DuncanCTOSell6,546$3.46$22,649.1627,572View SEC Filing  
12/12/2017Christine M KlaskinVPSell5,610$3.46$19,410.6069,943View SEC Filing  
12/12/2017Karen ValentineInsiderSell8,358$3.46$28,918.68109,879View SEC Filing  
10/30/2017Garo H ArmenCEOBuy100,000$3.55$355,000.00View SEC Filing  
4/12/2017Garo H ArmenCEOBuy100,000$3.35$335,000.001,389,021View SEC Filing  
2/14/2017Corp IncyteMajor ShareholderBuy10,000,000$6.00$60,000,000.0017,763,968View SEC Filing  
9/6/2016Ulf WiinbergDirectorBuy30,000$6.29$188,700.0030,000View SEC Filing  
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.001,346,026View SEC Filing  
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.0033,538View SEC Filing  
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.001,251,228View SEC Filing  
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.841,051,228View SEC Filing  
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.201,051,228View SEC Filing  
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.0010,000View SEC Filing  
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.001,409,607View SEC Filing  
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.0051,534View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agenus (NASDAQ AGEN) News Headlines

Source:
DateHeadline
Agenus: Buy, Sell Or Hold?Agenus: Buy, Sell Or Hold?
seekingalpha.com - May 18 at 5:15 PM
What Now For Agenus?What Now For Agenus?
seekingalpha.com - May 18 at 9:28 AM
Agenus to Present Clinical Data on Lead Programs at ASCO 2018Agenus to Present Clinical Data on Lead Programs at ASCO 2018
finance.yahoo.com - May 17 at 5:31 PM
Agenus -6.5% on at-the-market sales deal for 20M sharesAgenus -6.5% on at-the-market sales deal for 20M shares
seekingalpha.com - May 11 at 10:13 PM
BRIEF-Agenus Inc Files Prospectus Supplement Relates To Sale Of Up To 20 Mln Shares Of CoBRIEF-Agenus Inc Files Prospectus Supplement Relates To Sale Of Up To 20 Mln Shares Of Co
www.reuters.com - May 11 at 5:11 PM
Agenus (AGEN) Q1 Loss Wider than Expected, Shares DownAgenus' (AGEN) Q1 Loss Wider than Expected, Shares Down
www.nasdaq.com - May 8 at 5:03 PM
Agenus' (AGEN) Q1 Loss Wider than Expected, Shares DownAgenus' (AGEN) Q1 Loss Wider than Expected, Shares Down
finance.yahoo.com - May 8 at 5:02 PM
BRIEF-Agenus Inc Says Terminated Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & CoBRIEF-Agenus Inc Says Terminated Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co
www.reuters.com - May 8 at 8:51 AM
Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus UpdateYour Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update
seekingalpha.com - May 8 at 8:51 AM
Edited Transcript of AGEN earnings conference call or presentation 7-May-18 3:00pm GMTEdited Transcript of AGEN earnings conference call or presentation 7-May-18 3:00pm GMT
finance.yahoo.com - May 8 at 8:51 AM
BRIEF-Agenus Q1 Loss Per Share $0.53BRIEF-Agenus Q1 Loss Per Share $0.53
www.reuters.com - May 7 at 5:08 PM
Agenus (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call TranscriptAgenus' (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 5:08 PM
Agenus reports Q1 results; provides milestones for 2018Agenus reports Q1 results; provides milestones for 2018
seekingalpha.com - May 7 at 5:08 PM
Agenus (AGEN) Misses Q1 EPS by 23cAgenus (AGEN) Misses Q1 EPS by 23c
www.streetinsider.com - May 7 at 5:08 PM
Agenus: 1Q Earnings SnapshotAgenus: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:08 PM
Agenus Reports First Quarter 2018 Financial Results and Provides Corporate UpdateAgenus Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 7 at 5:08 PM
Agenus to Present at Deutsche Banks 43rd Annual Health Care Conference in BostonAgenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston
finance.yahoo.com - May 7 at 5:08 PM
Agenus (AGEN) Posts  Earnings Results, Misses Expectations By $0.17 EPSAgenus (AGEN) Posts Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - May 7 at 3:50 PM
$16.39 Million in Sales Expected for Agenus (AGEN) This Quarter$16.39 Million in Sales Expected for Agenus (AGEN) This Quarter
www.americanbankingnews.com - May 7 at 4:26 AM
 Brokerages Anticipate Agenus (AGEN) Will Announce Earnings of -$0.28 Per Share Brokerages Anticipate Agenus (AGEN) Will Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - May 5 at 9:32 AM
Agenus (AGEN) Upgraded to Hold at ValuEngineAgenus (AGEN) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 3:34 PM
Agenus (AGEN) Scheduled to Post Quarterly Earnings on MondayAgenus (AGEN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 4 at 10:12 AM
Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and WebcastAgenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast
finance.yahoo.com - May 3 at 4:55 PM
AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MAAgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA
finance.yahoo.com - May 1 at 8:57 AM
Will Agenus (AGEN) Disappoint Investors This Earnings Season?Will Agenus (AGEN) Disappoint Investors This Earnings Season?
finance.yahoo.com - April 30 at 4:51 PM
$16.39 Million in Sales Expected for Agenus Inc (AGEN) This Quarter$16.39 Million in Sales Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - April 20 at 4:28 AM
Agenus (AGEN) Downgraded by ValuEngine to SellAgenus (AGEN) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 18 at 11:22 PM
 Brokerages Expect Agenus Inc (AGEN) to Announce -$0.28 Earnings Per Share Brokerages Expect Agenus Inc (AGEN) to Announce -$0.28 Earnings Per Share
www.americanbankingnews.com - April 18 at 8:13 AM
Agenus (AGEN) Rating Increased to Buy at BidaskClubAgenus (AGEN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 7:35 PM
Agenus (AGEN) Upgraded to Sell by ValuEngineAgenus (AGEN) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 16 at 7:34 PM
Why Is Agenus (AGEN) Down 17.7% Since its Last Earnings Report?Why Is Agenus (AGEN) Down 17.7% Since its Last Earnings Report?
finance.yahoo.com - April 16 at 8:49 AM
Agenus (AGEN) Downgraded to Hold at BidaskClubAgenus (AGEN) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 14 at 8:31 AM
Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 ...Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 ...
www.prnewswire.com - April 11 at 4:59 PM
Will Agenus Inc’s (NASDAQ:AGEN) Earnings Grow Over The Next Few Years?Will Agenus Inc’s (NASDAQ:AGEN) Earnings Grow Over The Next Few Years?
finance.yahoo.com - April 11 at 4:59 PM
Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual MeetingThree Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting
finance.yahoo.com - April 11 at 4:59 PM
Agenus Inc (AGEN) Receives Average Recommendation of "Hold" from AnalystsAgenus Inc (AGEN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 1:24 AM
Agenus (AGEN) Rating Lowered to Strong Sell at BidaskClubAgenus (AGEN) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 7 at 7:02 AM
-$0.28 Earnings Per Share Expected for Agenus Inc (AGEN) This Quarter-$0.28 Earnings Per Share Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - April 1 at 7:23 AM
Agenus (AGEN) Stock Rating Lowered by BidaskClubAgenus (AGEN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 30 at 11:10 PM
Agenus (AGEN) Stock Rating Upgraded by Zacks Investment ResearchAgenus (AGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:18 PM
Agenus (AGEN) Rating Lowered to Sell at BidaskClubAgenus (AGEN) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 29 at 11:16 AM
Agenus to Present at Healthcare Investor Conferences In AprilAgenus to Present at Healthcare Investor Conferences In April
finance.yahoo.com - March 29 at 9:07 AM
Agenus (AGEN) Lifted to Buy at Zacks Investment ResearchAgenus (AGEN) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 28 at 12:58 PM
Agenus (AGEN) Upgraded by BidaskClub to BuyAgenus (AGEN) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 24 at 4:30 PM
Agenus (AGEN) Lowered to Sell at Zacks Investment ResearchAgenus (AGEN) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 20 at 1:16 PM
Brokers Issue Forecasts for Agenus Incs FY2022 Earnings (AGEN)Brokers Issue Forecasts for Agenus Inc's FY2022 Earnings (AGEN)
www.americanbankingnews.com - March 19 at 10:02 AM
Agenus Inc (AGEN) Expected to Post Q1 2019 Earnings of ($0.35) Per ShareAgenus Inc (AGEN) Expected to Post Q1 2019 Earnings of ($0.35) Per Share
www.americanbankingnews.com - March 19 at 6:46 AM
BidaskClub Downgrades Agenus (AGEN) to BuyBidaskClub Downgrades Agenus (AGEN) to Buy
www.americanbankingnews.com - March 18 at 7:10 PM
Edited Transcript of AGEN earnings conference call or presentation 15-Mar-18 3:00pm GMTEdited Transcript of AGEN earnings conference call or presentation 15-Mar-18 3:00pm GMT
finance.yahoo.com - March 18 at 8:50 AM
Agenus Inc (AGEN) Given Average Recommendation of "Buy" by BrokeragesAgenus Inc (AGEN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 1:36 AM

SEC Filings

Agenus (NASDAQ:AGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agenus (NASDAQ:AGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agenus (NASDAQ AGEN) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.